Intended for healthcare professionals


Pioglitazone may reduce cardiovascular events in high risk patients with prediabetes

BMJ 2016; 352 doi: (Published 19 February 2016) Cite this as: BMJ 2016;352:i1029
  1. Susan Mayor
  1. London

Pioglitazone, an insulin sensitising agent, may reduce the risk of myocardial infarction (MI) and stroke after a recent transient ischaemic attack (TIA) or stroke in patients without diabetes who are insulin resistant, a randomised trial has shown.1

The study investigated whether treating insulin resistance, which previous research has shown to affect more than half of people without diabetes who have an ischaemic stroke or TIA, could offer a new approach to reducing the subsequent risk of stroke …

View Full Text

Log in

Log in through your institution


* For online subscription